Cohance Lifesciences Limited has informed the Exchange about Options to purchase securities
COHANCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
The Nomination and Remuneration Committee of Cohance Lifesciences approved the grant of 1,98,711 stock options to eligible employees of the company and its subsidiaries under the ESOP 2023 scheme. Each option is convertible into one equity share of face value Re. 1, meaning up to 1,98,711 equity shares could be issued upon exercise. The scheme is in line with SEBI's Share Based Employee Benefits Regulations, 2021. Options will vest over a period of 1 to 10 years, and once vested, employees have up to 3 years to exercise them. This is a routine employee incentive disclosure with no immediate financial impact.
This is a standard ESOP grant with minor future dilution potential and no immediate effect on earnings or stock price. Retail investors should view it as a routine employee compensation event, though a large grant can slightly dilute existing shareholders if eventually exercised.